United Therapeutics, Liquidia settle Yutrepia patent litigation, agree to dismiss cases with prejudice

Bitget2026/10/14 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics reached a settlement with Liquidia to end multiple patent disputes tied to Yutrepia sales and labeling.
Liquidia must pay USD 185 million within 30 business days for past PH-ILD sales from June 2, 2025 through execution.
Liquidia also agreed to pay USD 145.4 million in two installments due by Jan. 31, 2027 and Apr. 30, 2027.
United Therapeutics will pay Liquidia USD 10 million to resolve a separate New Jersey case involving Sandoz and RareGen.
Claims against former Liquidia executive Robert Roscigno, as an individual, remain pending and were excluded from the releases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115723), on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

United Therapeutics, Liquidia settle Yutrepia patent litigation, agree to dismiss cases with prejudice

You may also like

Crypto prices